On July 16, 2025, Needham analyst Mike Matson reaffirmed his stance on Lucid Diagnostics (LUCD, Financial), maintaining a Buy rating for the company. This decision reflects ongoing confidence in the company's market potential and operational strategies.
The price target for Lucid Diagnostics (LUCD, Financial) remains steady at $3.00 USD, consistent with prior evaluations. This stability in price target indicates a sustained belief in the company's financial performance.
Investors of Lucid Diagnostics (LUCD, Financial) should note that there has been no change in the rating or price target, which underscores the analyst's continued positive outlook on the stock. The reiterated Buy rating suggests a robust potential for growth in the coming periods.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Lucid Diagnostics Inc (LUCD, Financial) is $3.79 with a high estimate of $7.75 and a low estimate of $2.00. The average target implies an upside of 224.07% from the current price of $1.17. More detailed estimate data can be found on the Lucid Diagnostics Inc (LUCD) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, Lucid Diagnostics Inc's (LUCD, Financial) average brokerage recommendation is currently 1.8, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Lucid Diagnostics Inc (LUCD, Financial) in one year is $4.76, suggesting a upside of 306.84% from the current price of $1.17. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Lucid Diagnostics Inc (LUCD) Summary page.
